8-K: XOMA Corp Reports Q1 2024 Results, Highlights Portfolio Expansion and Milestone Achievements

XOMA Corporation announced its first quarter 2024 financial results, showcasing revenue growth, strategic acquisitions, and key milestone achievements.

Summary

• XOMA Corporation reported a total revenue of $1.5 million for the first quarter of 2024, up from $0.4 million in the same period last year.
• The company's net loss for the quarter was $8.6 million, an improvement from the $9.8 million loss in the first quarter of 2023.
• XOMA acquired Kinnate Pharmaceuticals, adding at least $9.5 million in non-dilutive capital.
• They expanded their commercial royalty portfolio by acquiring interests in DSUVIA and XACIATO, as well as two Phase 3 assets.
• A $9 million milestone was earned upon FDA approval of Day One's OJEMDA, with XOMA also entitled to mid-single digit royalties on sales.
• XOMA launched a stock repurchase program for up to $50 million.
• The company had $142.4 million in cash and cash equivalents as of March 31, 2024.
• Operating expenses included $8.5 million in general and administrative costs, with $2.9 million in non-cash stock-based compensation.
• Interest expense was $3.6 million, related to the Blue Owl loan.

Sentiment

Score: 7

Explanation: The document presents a generally positive outlook with significant revenue growth, strategic acquisitions, and milestone achievements. However, the company is still operating at a loss and has some risks associated with its business model. The sentiment is therefore moderately positive.

Positives

• Revenue increased significantly year-over-year, indicating growth in the company's royalty and milestone portfolio.
• The acquisition of Kinnate Pharmaceuticals provides a boost to XOMA's balance sheet with non-dilutive capital.
• The expansion of the royalty portfolio with new commercial and Phase 3 assets diversifies XOMA's revenue streams.
• The FDA approval of OJEMDA triggered a substantial milestone payment and future royalty potential.
• The initiation of a stock repurchase program signals confidence in the company's financial position and future prospects.
• The net loss decreased compared to the same quarter last year.

Negatives

• The company reported a net loss of $8.6 million for the quarter.
• General and administrative expenses increased by $2.3 million compared to the same quarter last year.
• Interest expenses were $3.6 million due to the Blue Owl loan.
• Cash and cash equivalents decreased from $159.6 million at the end of 2023 to $142.4 million at the end of Q1 2024.
• Net cash used in operating activities was $4.9 million.

Risks

• The company's future performance is dependent on the success of its partners' drug development programs.
• There is no guarantee that investigational compounds will achieve commercial success.
• The company's financial results are subject to risks inherent in the biotechnology industry.
• The company's licensees may require substantial funds to continue development which may not be available.
• There is a risk that there will not be a viable market for the products in which XOMA has an ownership or royalty interest.
• If the therapeutic product candidates to which XOMA has a royalty interest do not receive regulatory approval, the third-party licensees will not be able to market them.

Future Outlook

The company anticipates potential commercial payments and regulatory approvals related to various assets in its portfolio, including VABYSMO, OJEMDA, XACIATO, IXINITY, DSUVIA, and arimoclomol. XOMA also expects the potential for substantial milestone and royalty proceeds over time.

Management Comments

• We continue to build the foundation for accelerating value creation with a disciplined approach to capital deployment, stated Owen Hughes, Chief Executive Officer of XOMA.
• In recent months, we've completed the acquisition of Kinnate, acquired economic interests in two commercial assets, as well as in two first-in-class Phase 3 assets, and initiated our first share buyback program on the heels of securing the VABYSMO royalty-backed loan with Blue Owl.

Industry Context

XOMA operates as a royalty aggregator, a business model that is becoming increasingly relevant in the biotech industry as companies seek non-dilutive funding options. The company's focus on acquiring future economics associated with therapeutic candidates aligns with the trend of biotech companies seeking to monetize their assets and accelerate drug development.

Comparison to Industry Standards

• XOMA's revenue growth from $0.4 million to $1.5 million year-over-year is a positive sign, but it is still relatively low compared to larger biotech companies with commercialized products.
• The company's net loss of $8.6 million is typical for a biotech company in its stage of development, but it is important to monitor the trend of losses over time.
• The acquisition of Kinnate Pharmaceuticals and the expansion of the royalty portfolio are strategic moves that could position XOMA for future growth, similar to other royalty-focused companies like Royalty Pharma.
• The initiation of a stock repurchase program is a positive signal to investors, but the size of the program ($50 million) is relatively small compared to larger, more established companies.
• XOMA's focus on acquiring royalty rights in various therapeutic areas is similar to other companies in the royalty aggregation space, but the specific assets and terms of the deals are unique to XOMA.

Stakeholder Impact

• Shareholders may benefit from the company's growth and potential future profitability.
• Employees may benefit from the company's expansion and success.
• Customers of XOMA's partners may benefit from the development of new therapeutic options.
• Suppliers and creditors may benefit from the company's financial stability and growth.

Next Steps

• XOMA will continue to monitor the progress of its partners' drug development programs.
• The company will focus on integrating Kinnate Pharmaceuticals and realizing the benefits of the acquisition.
• XOMA will continue to evaluate new opportunities to expand its royalty and milestone portfolio.
• The company will execute its stock repurchase program.
• XOMA will await the FDA PDUFA action date for arimoclomol on September 21, 2024.

Key Dates

Keywords

royalty aggregator, biotechnology, milestone payments, drug development, FDA approval, portfolio expansion, stock repurchase, financial results, Kinnate Pharmaceuticals, OJEMDA, DSUVIA, XACIATO